Molar, Third
Conditions
Interventions
This is a randomized, controlled, split-mouth, double-blind clinical trial. Group 1 (n = 5): oral administration of tramadol hydrochloride 100 mg associated with nimesulide 100 mg. Group 2 (n = 5): or
Sponsors
Universidade Federal dos Vales do Jequitinhonha e Mucuri
Universidade Federal dos Vales do Jequitinhonha e Mucuri
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients (=18 years old) treated at the Oral and Maxillofacial Surgery and Traumatology Clinic of UFVJM; bilateral indication for mandibular third molar extraction; asymptomatic; classified as class IIB according to Pell & Gregory, and with similar surgical difficulty
Exclusion criteria
Exclusion criteria: Exclusion criteria included allergy to study medications; recent use of anti-inflammatory drugs; autoimmune diseases; HIV infection; tuberculosis; pregnancy; lactation; history of pericoronitis; cognitive impairments or refusal to sign the informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the feasibility of a randomized clinical trial comparing the preemptive analgesic efficacy of Tramadol hydrochloride 100 mg combined with Nimesulide 100 mg versus Dexamethasone 8 mg and placebo in mandibular third molar extractions classified as Pell and Gregory class IIB | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactBrender Silva
Universidade Federal dos Vales do Jequitinhonha e Mucuri
Outcome results
None listed